Valo Health to Participate in SVB Leerink CybeRx Conference: Big Data, A.I. & Machine Learning in Healthcare
BOSTON, July 22, 2021 /PRNewswire/ -- Valo Health LLC (Valo), the technology company built to transform the drug discovery and development process using human-centric data and artificial intelligence driven compute, today announced that David Berry, Ph.D., Founder and Chief Executive Officer of Valo Health will participate in the SVB Leerink CybeRx: Big Data, A.I. & Machine Learning in Healthcare Conference on Tuesday, July 27, 2021, at 2:00 p.m. ET. Additional details are as follows:
AI/ML Frontiers - Drug Discovery & Development
David Berry, Ph.D. – Founder & CEO, Valo Health (Private)
Carl Halnson, Ph.D. - Director& CEO, AbCellera (ABCL)
Daphne Koller - Founder & CEO, Board Member, Insitro (Private)
Mary Rozenman, PH.D. - CFO/CBO, Insitro (Private)
Christopher Gibson, Ph.D. - Co-Founder & CEO, Recursion Pharmaceuticals, Inc. (RXRX)
About Valo Health
Valo Health, LLC ("Valo") is a technology company built to transform the drug discovery and development process using human-centric data and artificial intelligence driven computation. As a digitally native company, Valo aims to fully integrate human-centric data across the entire drug development life cycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing costs, time, and failure rates. The company's Opal Computational Platform™ is an integrated set of capabilities designed to transform data into valuable insights that may accelerate discoveries and enable Valo to advance a robust pipeline of programs across cardiovascular metabolic renal, oncology, and neurodegenerative disease. Founded by Flagship Pioneering and headquartered in Boston, MA, Valo also has offices in Lexington, MA, San Francisco, CA, Princeton, NJ, and Branford, CT. To learn more, visit www.valohealth.com.
SOURCE Valo Health, LLC
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article